Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Items 301–400 of 863
Asmar, N. E., Rajpal, A., Selman, W. R., & Arafah, B. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01797 · Cited by 26
Computer Vision Technology in the Differential Diagnosis of Cushing’s Syndrome
Popp, K. H., Kosilek, R. P., FROHNER, R. N., Stalla, G. K., Athanasoulia-Kaspar, A. P., Berr, C., Zopp, S., Reincke, M., Witt, M., Würtz, R. P., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0887-4233 · Cited by 27
Self-citationGeer, E. B., Salvatori, R., Elenkova, A. P., Fleseriu, M., Pivonello, R., Witek, P., Feelders, R. A., Bex, M., Borresen, S. W., Puglisi, S., et al. (2020) · Pituitary · doi:10.1007/s11102-020-01103-6 · Cited by 25
“Surgery to remove the underlying neoplasia causing excess cortisol production is typically the first-line treatment for CS [7, 8].”
BackgroundSelf-citationOutcomes After Repeat Transsphenoidal Surgery for Recurrent Cushing Disease: Updated
Burke, W. T., Penn, D. L., Repetti, C. S., Iuliano, S., & Laws, E. R. (2019) · Neurosurgery · doi:10.1093/neuros/nyz193 · Cited by 25
Shahrestani, S., Cardinal, T. M., Micko, A. S. G., Strickland, B. A., Pangal, D. J., Kugener, G., Weiss, M. H., Carmichael, J. D., & Zada, G. (2021) · Pituitary · doi:10.1007/s11102-021-01128-5 · Cited by 24
Dai, C., Feng, M., Sun, B., Bao, X., Yao, Y., Deng, K., Ren, Z.-Y., Zhao, B., Lü, L., Wang, R., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02848-1 · Cited by 24
Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells
Sugiyama, A., Kageyama, K., Murasawa, S., Ishigame, N., Niioka, K., & Daimon, M. (2014) · Pituitary · doi:10.1007/s11102-014-0607-4 · Cited by 24
Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics
Pozza, C., Graziadio, C., Giannetta, E., Lenzi, A., & Isidori, A. M. (2012) · Journal of Oncology · doi:10.1155/2012/685213 · Cited by 24
Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea
Hur, K. Y., Kim, J. H., Kim, B.-J., Kim, M., Lee, E. J., & Kim, S.-W. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.7 · Cited by 24
Stewart, P. M., & Newell-Price, J. D. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00015-0 · Cited by 35
Self-citationParaneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms
Guilmette, J. M., & Nosé, V. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.03.002 · Cited by 27
Endocrine hypertension - Cushing′s syndrome
Singh, Y., Kotwal, N., & Menon, A. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.86973 · Cited by 23
“Indian Journal of Endocrinology and Metabolism / 2011 / Vol 15 / Supplement 4 S316 Patients with persistence of hypercortisolism postoperatively can be subjected to repeat surgery, radiotherapy or bilateral adrenalectomy[17] Pituitary radiation (conventional or gamma knife) has been recommended as a means to treat Cus…”
BackgroundYoshida, K., Fukuoka, H., Odake, Y., Nakajima, S., Tachibana, M., Ito, J., Hosokawa, Y., Yamada, T., Miura, H., Suematsu, N., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00375 · Cited by 23
Using subscales when scoring the Cushing's quality of life questionnaire
Tiemensma, J., Depaoli, S. A., & Felt, J. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0640 · Cited by 23
Multicenter external validation of the Zurich Pituitary Score
Staartjes, V. E., Serra, C., Zoli, M., Mazzatenta, D., Pozzi, F., Locatelli, D., d’Avella, E., Solari, D., Cavallo, L. M., & Regli, L. (2020) · Acta Neurochirurgica · doi:10.1007/s00701-020-04286-w · Cited by 23
“Biochemical remission (BR) was defined as normalization of hypersecretion into the normal reference range as defined by accepted international guidelines [2, 14].”
MethodTritos, N. A., Fazeli, P. K., McCormack, A. I., Mallea-Gil, S., Pineyro, M. M., Christ‐Crain, M., Frara, S., Labadzhyan, A., Ioachimescu, A. G., Shimon, I., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01170-3 · Cited by 23
Self-citationAlba, E. L., Japp, E., Fernandez-Ranvier, G. G., Badani, K. K., Wilck, E. J., Ghesani, M. V., Wolf, A., Wolin, E. M., Corbett, V., Steinmetz, D., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac073 · Cited by 26
“Biochemical testing with HDDST and/or vasopressin and CRH stimulation testing may not reliably identify the source of ACTH, with discordant results in up to 33% of patients [10].”
MethodChazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Endocrine hypertension — Current understanding and comprehensive management review
Sukor, N. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.05.004 · Cited by 26
Perioperative management of patients undergoing transsphenoidal pituitary surgery.
Zada, G., Woodmansee, W. W., Iuliano, S., & Laws, E. R. (2010) · PubMed Central · Cited by 26
Development of potent selective competitive-antagonists of the melanocortin type 2 receptor
Bouw, E., Huisman, M., Neggers, S. J. C. M. M., Themmen, A. P. N., van der Lely, A. J., & Delhanty, P. J. D. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.003 · Cited by 22
“Surgery is still the first choice of treatment for ACTH-dependent Cushing’s syndrome (Biller et al., 2008; Fleseriu and Petersenn, 2012).”
BackgroundBilateral Adrenalectomy: Lifesaving Procedure in Severe Cushing Syndrome
Han, J. Y., Mirsadraei, L., Yeh, M. W., Suh, J. D., Yong, W. H., Bergsneider, M., & Heaney, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11315.cr · Cited by 22
Pasireotide for the treatment of Cushing's disease
Arnaldi, G., & Boscaro, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.495943 · Cited by 23
“and, according to recent guidelines, transsphenoidal surgical excision of the corticotroph pituitary adenoma is the firstline therapy [5].”
BackgroundInfluentialSelf-citationTrementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Polenta, B., Spinello, M., Boscaro, M., & Arnaldi, G. (2014) · Pituitary · doi:10.1007/s11102-014-0557-x · Cited by 23
Self-citationiMRI During Transsphenoidal Surgery
Chittiboina, P. (2017) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2017.05.005 · Cited by 22
Li, R., Zhang, Z., Wang, J., Huang, Y., Sun, W., Xie, R., Hu, F., & Lei, T. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.127 · Cited by 23
Simeoli, C., Ferrigno, R., Martino, M. C. D., Iacuaniello, D., Papa, F., Angellotti, D., Pivonello, C., Patalano, R., Negri, M., Colao, A. A. L., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01077-8 · Cited by 24
“Therefore, additional second-line treatments are frequently required, such as repeat pituitary surgery, pituitary radiotherapy, bilateral adrenalectomy, and medical therapy [1, 6, 7].”
BackgroundInfluentialSelf-citationEndocrine Outcomes After Pituitary Surgery
Buttan, A. K., & Mamelak, A. N. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.05.009 · Cited by 23
Nadezhdina, E. Y., Rebrova, O. Y., Grigoriev, A. Y., Иващенко, О. В., Неронович, А. В., Mel'nichenko, G. A., & Dedov, I. I. (2019) · Pituitary · doi:10.1007/s11102-019-00985-5 · Cited by 23
Kim, J. H., Shin, C. S., Paek, S. H., Jung, H., Kim, S. W., & Kim, S.-Y. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0109 · Cited by 23
Medical Management of Functioning Pituitary Adenoma: An Update
Oki, Y. (2014) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2014-0239 · Cited by 22
Budyal, S. R., Lila, A. R., Jalali, R., Gupta, T., Kasliwal, R., Jagtap, V. S., Bandgar, T., Menon, P. S. N., & Shah, N. S. (2013) · Pituitary · doi:10.1007/s11102-013-0466-4 · Cited by 22
Etomidate in Severe Cushing Syndrome: A Systematic Review
Muthukuda, D. T., Liyanarachchi, K., Jayawickreme, K. P., Mahesh, P. K. B., Ruwanga, V. G. D., Kumar, S., Subasinghe, C. J., & Newell-Price, J. D. C. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf039 · Cited by 21
“Etomidate could be successfully used in palliative settings as well, in combination with chemotherapy, immunotherapy, and other medical therapies as bridging or long-term therapy in settings with facilities for IV drug administration such as in hospice [55, 63].”
Self-citationKuo, C., Yen, Y., Wu, J., Chen, Y., Huang, W., & Cheng, H. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.04.059 · Cited by 21
Bancos, I., Hatipoğlu, B., Yuen, K. C. J., Chandramohan, L., Chaudhari, S., & Moraitis, A. G. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100256 · Cited by 24
“While surgical resection of the underlying tumor is usually the first-line treatment for patients with endogenous CS [22,23], after failed surgery, tumor recurrence, or in patients not eligible for surgery, pharmacological reduction of cortisol activity can also be achieved with GR antagonists.”
BackgroundMidzak, A. S., Akula, N., Rone, M. B., & Papadopoulos, V. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.023 · Cited by 20
Outcomes of endoscopic transsphenoidal surgery for Cushing's disease
Brady, Z., Garrahy, A., Carthy, C., O’Reilly, M., Thompson, C. J., Sherlock, M., Agha, A., & Javadpour, M. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00679-9 · Cited by 23
“8 μg/L) at day 3 postoperatively to allow early indication of biochemical remission [10, 11, 26–28]; the literature suggests this cutoff is associated with remission, and a low recurrence rate of approximately 10% at 10 years [14].”
BackgroundCushing disease in pediatrics: an update
Concepción‐Zavaleta, M. J., Flórez, C. D. A., Aldave, J. E. Q., García-Villasante, E. J., Gariza-Solano, A. C., Durand‐Vásquez, M. D. C., Urteaga, L. A. C., & Zavaleta‐Gutiérrez, F. E. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346074.037 · Cited by 20
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives
Cuny, T., Barlier, A., Feelders, R. A., Weryha, G., Hofland, L. J., Ferone, D., & Gatto, F. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.10.002 · Cited by 21
Self-citationEndoscopic bilateral adrenalectomy in patients with ectopic Cushing’s syndrome
Alberda, W. J., van Eijck, C. H. J., Feelders, R. A., Geert Kazemier, M., de Herder, W. W., & Burger, J. W. A. (2011) · Surgical Endoscopy · doi:10.1007/s00464-011-2020-7 · Cited by 20
Brito, L. P., Lerário, A. M., Bronstein, M. D., Soares, I. C., Mendonca, B. B., & Fragoso, M. C. B. V. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0047 · Cited by 21
Outcomes of Primary Transsphenoidal Surgery in Cushing Disease: Experience of a Tertiary Center
Keskin, F. E., Özkaya, H. M., Bolayırlı, M., Erden, S., Kadıoğlu, P., Tanrıöver, N., & Gazioğlu, N. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.07.014 · Cited by 20
Dai, C., Fan, Y., Liu, X.-H., Bao, X., Yao, Y., Wang, R., & Feng, M. (2020) · Neuroendocrinology · doi:10.1159/000509221 · Cited by 21
Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery
de Vries, F., Lobatto, D. J., Verstegen, M. J. T., Schutte, P. J., Notting, I. C., Kruit, M. C., Ahmed, S. F., Pereira, A. M., van Furth, W. R., & Biermasz, N. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab138 · Cited by 21
Barkhoudarian, G., Cutler, A. R., Yost, S., Lobo, B. M., Eisenberg, A., & Kelly, D. F. (2015) · Pituitary · doi:10.1007/s11102-015-0664-3 · Cited by 20
Yacqub‐Usman, K., Duong, C. V., Clayton, R. N., & Farrell, W. E. (2013) · Endocrinology · doi:10.1210/en.2013-1061 · Cited by 20
Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report
Conners, K., Woods, S. E., & Webb, M. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-318 · Cited by 20
“When surgical therapy is not an option, ketoconazole is the best therapy for treating patients with SCLC and ectopic ACTH secretion [8].”
BackgroundNelson Syndrome: Update on Therapeutic Approaches
Azad, T. D., Veeravagu, A., Kumar, S., & Katznelson, L. J. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.01.038 · Cited by 24
Severe hypercortisolism: A medical emergency requiring urgent intervention
Lutgers, H. L., Vergragt, J., Dong, P.-V., de Vries, J., Dullaart, R. P. F., van den Berg, G., & Ligtenberg, J. J. M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e47b7a · Cited by 20
“The deleterious effect of hypercortisolism temporarily can be inhibited by pharmacologic interventions (17).”
BackgroundPituitary-targeted medical therapy of Cushing's disease
Alexandraki, K., & Grossman, A. B. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.669 · Cited by 20
Self-citationThe management of Cushing's disease - from investigation to treatment.
Juszczak, A., & Grossman, A. B. (2013) · PubMed · Cited by 21
Self-citationShichi, H., Fukuoka, H., Kanzawa, M., Yamamoto, M., Yamamoto, N., Suzuki, M., Urai, S., Matsumoto, R., Kanie, K., Fujita, Y., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01220-4 · Cited by 19
Treatment Options in Cushing's Disease
Rizk, A., Honegger, J. B., Milian, M., & Psaras, T. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6198 · Cited by 22
Shapiro, L., Elahi, S., Riddoch, F., Perry, L., Martin, L., Akker, S. A., Monson, J. P., Drake, W. M., Grossman, A. B., Savage, M. O., et al. (2016) · Hormone Research in Paediatrics · doi:10.1159/000446913 · Cited by 21
Self-citationInoue, M., Okamura, K., Kitaoka, C., Kinoshita, F., Namitome, R., Nakamura, U., Shiota, M., Gotō, K., Ohtsubo, T., Matsumura, K., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0025 · Cited by 19
“Adrenocorticotrophin (ACTH)-dependent Cushing’s syndrome is a heterogeneous disorder requiring a multi‐ disciplinary and individualized approach to patient man‐ agement [1].”
BackgroundGuaraldi, F., Zoli, M., Asioli, S., Corona, G., Gori, D., Friso, F., Pasquini, E., Bacci, A., Sforza, A., & Mazzatenta, D. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01225-5 · Cited by 19
Chen, X., Liang, H., Hu, K., Sun, Q., Sun, B., Bian, L., & Sun, Y. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001656 · Cited by 19
Alshaikh, O. M., Almahfouz, A., Al‐Hindi, H., Mahfouz, A. B., & Alzahrani, A. S. (2010) · Endocrine Practice · doi:10.4158/ep09243.cr · Cited by 20
Effective Long-Term Treatment of Cushing’s Disease with Pasireotide: A Case Report
Lü, L., Duan, L., Jin, Z., Lu, Z., & Gu, F. (2013) · Endocrine Practice · doi:10.4158/ep12296.cr · Cited by 18
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series
Serban, A. L., Sindaco, G. D., Sala, E., Carosi, G., Indirli, R., Rodari, G., Giavoli, C., Locatelli, M., Carrabba, G. G., Bertani, G., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01151-1 · Cited by 18
Cortical thickness abnormalities in long-term remitted Cushing’s disease
Bauduin, S., van der Pal, Z., Pereira, A. M., Meijer, O. C., Giltay, E. J., van der Wee, N. J. A., & van der Werff, S. J. A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00980-6 · Cited by 18
Campo, M. R., Lamacchia, O., Farese, A., Conserva, A., Picca, G., Grilli, G., & Cignarelli, M. (2014) · HORMONES · doi:10.14310/horm.2002.1514 · Cited by 18
“As medical therapy of hypercortisolism is still far from providing effective and well-tolerated drugs, adrenal surgery remains the definitive solution to the syndrome.(7) Mitotane treatment [o,p’-DDD(1-(o-chlorophenyl)-1(p-chlorophenyl)-2,2-dichloro-ethane)] is widely used in the treatment of adrenocortical carcinoma…”
BackgroundKreitschmann‐Andermahr, I., Siegel, S., Gammel, C., Campbell, K. K., Edwin, L., Grzywotz, A., Kuhna, V., Kołtowska‐Häggström, M., Müller, O. J., Buchfelder, M., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9014768 · Cited by 18
“If hypercortisolism cannot be normalized by these measures, radiotherapy, steroid-lowering medications, or bilateral adrenalectomy may also be employed in patients with endogenous CS and CD [11, 12].”
BackgroundSelf-citationBusceti, C. L., Ferese, R., Bucci, D., Ryskalin, L., Gambardella, S., Madonna, M., Nicoletti, F., & Fornai, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122901 · Cited by 19
Effect of primary empty sella syndrome on pituitary surgery for Cushing's disease: Clinical article
Mehta, G. U., Bakhtian, K. D., & Oldfield, E. H. (2014) · Journal of neurosurgery · doi:10.3171/2014.3.jns132012 · Cited by 17
Neychev, V. K., Steinberg, S. M., Yang, L., Mehta, A. R., Nilubol, N., Keil, M. F., Nieman, L. K., Stratakis, C. A., & Kebebew, E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4605-1 · Cited by 19
Self-citationClinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease
Rebollar‐Vega, R., Zuarth-Vázquez, J. M., & Hernández-Ramírez, L. C. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102899 · Cited by 17
Nakada, Y., Kageyama, K., Sugiyama, A., Desaki, R., Takayasu, S., Niioka, K., Murasawa, S., Ishigame, N., Asari, Y., Iwasaki, Y., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0369 · Cited by 17
Donofrio, C. A., Losa, M., Gemma, M. F., Giudice, L., Barzaghi, L. R., & Mortini, P. (2016) · Endocrine · doi:10.1007/s12020-016-1214-0 · Cited by 18
Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas
Aydın, S., Çomunoğlu, N., Ahmedov, M. L., Korkmaz, Ö. P., Öz, B., Kadıoğlu, P., Gazioğlu, N., & Tanrıöver, N. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.06.217 · Cited by 17
Galiana, P. A., Fajardo, C., Suárez, P. A. R., Gómez-Vela, J., Escrivá, C., & Rovira-Lillo, V. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.09.009 · Cited by 18
Witek, P., Zieliński, G., Szamotulska, K., Witek, J., & Zgliczyński, W. (2012) · PubMed · Cited by 21
TSP‐1 is downregulated and inversely correlates with miR‐449c expression in Cushing's disease
Ren, J., Gu, C., Yang, Y., Xue, J., Sun, Y., Jian, F., Chen, D., Bian, L., & Sun, Q. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14297 · Cited by 17
Fleseriu, M., Iweha, C., Salgado, L. R., Mazzuco, T. L., Campigotto, F., Maamari, R., & Limumpornpetch, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00436 · Cited by 18
“Bilateral adrenalectomy can result in complete resolution of hypercortisolism, but it renders patients glucocorticoid and mineralocorticoid deficient and may also lead to corticotroph tumor progression (Nelson’s syndrome), which is characterized by pituitary tumor expansion coupled with high ACTH concentrations (11).”
BackgroundInfluentialLiu, Q., Zang, J., Yang, Y., Ling, Q. D., Wu, H., Wang, P., Lü, L., & Zhu, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05370-8 · Cited by 18
Hara, Y., Teshima, T., TAODA, T., Ishino, H., Nezu, Y., Harada, Y., Yogo, T., Masuda, H., Teramoto, A., & TAGAWA, M. (2010) · Journal of Veterinary Medical Science · doi:10.1292/jvms.09-0367 · Cited by 16
Kidney Stones as an Underrecognized Clinical Sign in Pediatric Cushing Disease
Rahman, S. H., Papadakis, G. Z., Keil, M. F., Faucz, F. R., Lodish, M. B., & Stratakis, C. A. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.11.045 · Cited by 16
“The most common cause of endogenous CS is adrenocorticotrophic hormone (ACTH) overproduction from a pituitary adenoma, or Cushing disease (CD).(3,4) CD accounts for 75% of all cases of CS in children aged >7 years, and can have long-term effects on growth and development.”
Asari, Y., Kageyama, K., Nakada, Y., Tasso, M., Takayasu, S., Niioka, K., Ishigame, N., & Daimon, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s141345 · Cited by 16
Chan, C., & Roberts, J. M. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221580 · Cited by 16
Gamma Knife radiosurgery for the treatment of Nelson’s syndrome: a multicenter, international study
Cordeiro, D. P., Xu, Z., Li, C., Iorio‐Morin, C., Mathieu, D., Sisterson, N. D., Kano, H., Attuati, L., Picozzi, P., Sheehan, K. A., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.4.jns19273 · Cited by 16
Characterization of persistent and recurrent Cushing’s disease
Sundaram, N. K., Carluccio, A. L., & Geer, E. B. (2013) · Pituitary · doi:10.1007/s11102-013-0511-3 · Cited by 19
Jain, V., Metherell, L., David, A., Sharma, R., Sharma, P. K., Clark, A. J. L., & Chan, L. F. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0581 · Cited by 17
Ectopic ACTH Production Leading to Diagnosis of Underlying Medullary Thyroid Carcinoma
Matheny, L. N., Wilson, J. R., & Baum, H. B. A. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616643989 · Cited by 17
“In cases of Cushing’s disease, pituitary-directed therapies such as the somatostatin analog pasireotide and the dopamine agonist cabergoline are also available.(5) However, with the exception of pasireotide, all of these therapies are oral, and may not be feasible in times of critical illness or in the face of intesti…”
BackgroundNewell-Price, J. D. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1622 · Cited by 16
Self-citationNeurosurgical treatment of Cushing disease
Sheth, S. A., Bourne, S. K., Tritos, N. A., & Swearingen, B. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.006 · Cited by 15
Self-citationCui, Q., Liu, X., Sun, Q., Sun, W., Zheng, H., He, M., Zhang, Z., Ma, Z., Shen, M., Shou, X., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03405-8 · Cited by 15
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome
Geer, E. B., Grillo, I., Li, Q., Robins, H., Cohen, V. V., Baratz, H. Q., Garcia, C., Sazo, M., Lin, A. L., Cohen, M. A., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01450-8 · Cited by 15
“Criteria for remission were based on Endo-crine Society consensus statement and recent guidelines [27, 28].”
MethodCurrent approaches to the pharmacological management of Cushing's disease
Molitch, M. E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.021 · Cited by 15
Systemic therapy of Cushing’s syndrome
Eckstein, N., Haas, B., Hass, M. D. S., & Pfeifer, V. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0122-8 · Cited by 22
“emphasized clinical management of CS as a multi-disciplinary approach on an individualized basis [66].”
BackgroundUSP8: a novel therapeutic target for Cushing’s disease
Jian, F., Cao, Y., Bian, L., & Sun, Q. (2015) · Endocrine · doi:10.1007/s12020-015-0682-y · Cited by 15
Cushing disease with pregnancy
Gopal, R. A., Acharya, S. V., Bandgar, T., Menon, P. S., & Shah, N. S. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.632789 · Cited by 16
Alwani, R. A., de Herder, W. W., de Jong, F. H., Lamberts, S. W. J., van der Lely, A. J., & Feelders, R. A. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04130.x · Cited by 15
Dutta, A., Gupta, N., Walia, R., Bhansali, A. K., Dutta, P. R., Bhadada, S. K., Pivonello, R., Ahuja, C. K., Dhandapani, S., Hajela, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01495-z · Cited by 15
Pituitary surgery in Cushing’s disease: first line treatment and role of reoperation
Jones, P. S., & Swearingen, B. (2022) · Pituitary · doi:10.1007/s11102-022-01254-8 · Cited by 16
Self-citationManagement of Cushing's Disease After Failed Surgery - A Review
McLaughlin, N., Kassam, A. B., Prevedello, D. M., & Kelly, D. F. (2011) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710012075x · Cited by 15
Manavela, M. P., Danilowicz, K., & Bruno, O. D. (2011) · Pituitary · doi:10.1007/s11102-011-0309-0 · Cited by 15
A rare case of Cushing syndrome by cyclic ectopic-ACTH
Farage, M., Costa, M. A. D. D. L., & Godoy‐Matos, A. F. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000500008 · Cited by 15
Childhood Cushing Disease: A Challenge in Diagnosis and Management
Shah, N. S., & Lila, A. R. (2011) · Hormone Research in Paediatrics · doi:10.1159/000329173 · Cited by 17
“The reported complication rate is TreatmentManagement of CD aims at reversal of clinical features, normalization of hypothalamic-pituitary axis functioning and long-term control of the disease. Surgery Transsphenoidal surgery (TSS) with selective adenomectomy by an experienced surgeon is the treatment of choice [”
BackgroundCorsello, S. M., Senes, P., Iezzi, R., Rufini, V., Congedo, M. T., Paragliola, R. M., & Pontecorvi, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4359 · Cited by 15
Ectopic Adrenocorticotropic Hormone–Secreting Pituitary Adenomas: An Underestimated Entity
Knappe, U. J., Jaspers, C., Buschsieweke, D., Reinbold, W., Al-Omari, A., Saeger, W., Ehlenz, K., Mann, W. A., Kann, P. H., & Feldkamp, J. (2017) · Neurosurgery · doi:10.1227/neu.0000000000001319 · Cited by 16
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.